Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PMM2 | O15305 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11049330 | 0.85 | VCAM1 (0.47) | VCAM1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL14486448 | 0.85 | ERN1 (0.38) | VCAM1ALDH1A1TDP1HSP90AA1PMM2 | |
| SCHEMBL30644796 | 0.77 | TSHR (0.43) | VCAM1ALDH1A1TDP1TSHRPMM2 | |
| SCHEMBL11356037 | 0.76 | TDP1 (0.45) | VCAM1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL25171482 | 0.74 | PTGER4 (0.41) | VCAM1ALDH1A1TDP1TSHRPMM2 | |
| SCHEMBL3469093 | 0.73 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRPMM2MPI | |
| SCHEMBL30729476 | 0.73 | PTGER4 (0.50) | VCAM1ALDH1A1TDP1TSHRPMM2 | |
| SCHEMBL16175008 | 0.73 | PTGER4 (0.50) | VCAM1ALDH1A1TDP1TSHRPMM2 | |
| SCHEMBL5583401 | 0.73 | VCAM1 (0.51) | VCAM1ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL27927484 | 0.72 | ALDH1A1 (0.50) | ALDH1A1TDP1MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4512801-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | VCAM1 1976/4885ALDH1A1 1515/4885TDP1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.